Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Mar 31, 2026 · Filed Mar 31, 2026
Cytokinetics's Chief Commercial Officer sold $237K of Cytokinetics shares. It happened by itself, for taxes or pay.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$236,535
Shares × reported transaction price
35 days after results of Feb 24, 2026, 35 days before results of May 5, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.3% | +3.2% | −4.4% |
| 30 days | −4.9% | +10.0% | −14.9% |
| 90 days | +27.9% | +14.0% | +13.9% |
| 180 days | −0.7% | +16.8% | −17.5% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Officer sold ~$949K of Cytokinetics
Automatic saleDerivative exercise or conversion — not an open-market buy.